PRIVACY 
Your research and hospital records are confidential. Your name or any other 
personally identifying information will not be used in reports or publications 
resulting from this study. The National Institute of Health or other authorized 
agencies may inspect your records. A qualified representative of the National 
Cancer Institute may inspect the patient/study records. 
RIGHT TO REFUSE OR WITHDRAW 
The choice to enter or not to enter this study is yours. You are in a position to 
make a decision if you understand what the doctor has explained and what you have 
read about the research study and other possible forms of care. If you decide not 
to participate the other choices are available to you without prejudice. If you begin 
the study, you will have a right to withdraw at any time. If you should withdraw, 
you will be offered other available care which suits your needs and medical 
condition. 
TERMINATION OF STUDY 
Your participation in this research study may be ended without your consent for the 
following reasons: 
1. If your tumor does not respond or gets substantially larger during treatment. 
2. If the doctors treating you see side effects that they consider dangerous. 
3. If you refuse to have treatment as recommended by your doctor or if you 
refuse to have the tests needed to determine whether the treatment is safe 
and effective. 
This research study has been reviewed by the Memorial Sloan-Kettering Cancer 
Center Institutional Review Board the NIH Recombinant DNA Advisory 
Committee. The Memorial Board is legally responsible for making sure that 
research with patients is appropriate and that the patient’s rights and welfare are 
protected. 
The physicians in charge of this research study are Dr. Alan Houghton, telephone 
number (212) 639-7595, and Dr. Bemd Gansbacher, telephone number (212) 
639-5019. If you need more information about this study before you decide to 
Recombinant DNA Research, Volume 15 
[913] 
